Sunday - May 19, 2024
New Phase 1 Data From Memorial Sloan Kettering Cancer Center Shows an Investigational Cancer Vaccine May Elicit Lasting Immune Response in Patients With Pancreatic Cancer
April 08, 2024
NEW YORK, April 8 (TNSres) -- The Memorial Sloan Kettering Cancer Center issued the following news release on April 7, 2024:

New data presented today by Memorial Sloan Kettering Cancer Center (MSK) researchers show an experimental approach to treating pancreatic cancer with the messenger RNA (mRNA)-based therapeutic cancer vaccine candidate, autogene cevumeran, continues to show potential to stimulate an immune response that may reduce the risk of the disease returning after surgery . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products